Subscribe
pabradyphoto-2-
pabradyphoto / iStockphoto.com
31 August 2017Americas

FTC orders Baxter to divest rights in Claris deal

The Federal Trade Commission (FTC) has approved a final order combating the anticompetitive effects resulting from Baxter’s proposed $625 million acquisition of Claris’s injectable drugs business.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
Baxter sues B.Braun in revived kidney treatment patent dispute
16 November 2020   American healthcare multinational Baxter has accused B.Braun of patent infringement and fraudulent misrepresentation in an on-going dispute over products used to treat acute kidney injury.
Medtech
Federal Circuit affirms PTAB’s Baxter ruling
11 March 2021   The US Court of Appeals for the Federal Circuit has affirmed decisions from the Patent Trial and Appeal Board, knocking out two Baxter patents.


Editor's picks

Americas
Amgen set for ‘at-risk’ launch of blockbuster eye drug biosimilar
24 October 2024

Editor's picks

Americas
Amgen set for ‘at-risk’ launch of blockbuster eye drug biosimilar
24 October 2024

More on this story

Americas
Baxter sues B.Braun in revived kidney treatment patent dispute
16 November 2020   American healthcare multinational Baxter has accused B.Braun of patent infringement and fraudulent misrepresentation in an on-going dispute over products used to treat acute kidney injury.
Medtech
Federal Circuit affirms PTAB’s Baxter ruling
11 March 2021   The US Court of Appeals for the Federal Circuit has affirmed decisions from the Patent Trial and Appeal Board, knocking out two Baxter patents.

More on this story

Americas
Baxter sues B.Braun in revived kidney treatment patent dispute
16 November 2020   American healthcare multinational Baxter has accused B.Braun of patent infringement and fraudulent misrepresentation in an on-going dispute over products used to treat acute kidney injury.
Medtech
Federal Circuit affirms PTAB’s Baxter ruling
11 March 2021   The US Court of Appeals for the Federal Circuit has affirmed decisions from the Patent Trial and Appeal Board, knocking out two Baxter patents.

More features

President Trump 2.0: Five major areas to watch
Startup CFO’s betrayal is a lesson in preparing for the worst
Sandoz lands reduced antitrust award of $70m
New president’s to-do list: Patent bills, non-competes, USPTO director?
Sanofi subsidiary fends off $450m trade secrets case
Regulatory expert joins White & Case
Teva faces $500m fine for antitrust breaches over MS drug
UK Budget: A missed opportunity?